| Christen Lehmann, PHARMD | |
|
16105 Manchester Rd, Ellisville, MO 63011-2001 | |
| (636) 391-3202 | |
| Not Available |
| Full Name | Christen Lehmann |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 16105 Manchester Rd, Ellisville, Missouri |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538771589 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 2015022704 (Missouri) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Christen Lehmann, PHARMD 16105 Manchester Rd, Ellisville, MO 63011-2001 Ph: (636) 391-3202 | Christen Lehmann, PHARMD 16105 Manchester Rd, Ellisville, MO 63011-2001 Ph: (636) 391-3202 |
News Archive
A team of Montr-al researchers at the IRCM led by Dr. Nabil G. Seidah, in collaboration with Dr. William C. Wetsel's team at Duke University in the United States, discovered that the protein PC7 plays a critical role in the brain by affecting certain types of cognitive performance such as anxiety, learning and emotional memory. Their results, recently published in the scientific journals Proceedings of the National Academy of Sciences (PNAS) and Nature, could have a significant impact on regulating behaviour related to anxiety disorders and trauma.
In a recent study, combat exposure among Army enlisted women was associated with an increased likelihood of developing behavioral health problems post-deployment, including post-traumatic stress disorder (PTSD), depression, and at-risk drinking.
Men with prostate cancer run the risk of brittle bones as a side-effect of their treatment. But one hour's football training a few times a week counters many of the negative effects of the treatment, according to University of Copenhagen scientists.
Lux Biosciences, Inc. today announced its submission of simultaneous regulatory filings to both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking marketing approval for its investigational drug LUVENIQ™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.
Independent evaluators have found that measurable progress in reducing the rates of some targeted HAIs has been achieved under the umbrella of a national plan to prevent HAIs that was developed by the U.S. Department of Health and Human Services (HHS).
› Verified 2 days ago
Mr. Musadiq Jeddy, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 15846 Manchester Rd, Ellisville, MO 63011 Phone: 636-527-5074 | |
Madison Elisabeth Harper, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 15846 Manchester Rd, Ellisville, MO 63011 Phone: 309-202-3394 Fax: 636-527-6456 | |
Mrs. Cortney Renae Robinson, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 16105 Manchester Rd, Ellisville, MO 63011 Phone: 636-391-3202 | |
Mr. Jeffrey L Marlow, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 15909 Manchester Rd, Ellisville, MO 63011 Phone: 636-391-4064 Fax: 636-527-7385 | |
Linda Lui, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 16105 Manchester Rd, Ellisville, MO 63011 Phone: 636-391-3202 | |
Dr. Richard Briggs, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 15846 Manchester Rd, Ellisville, MO 63011 Phone: 636-527-6074 | |
Hawa Awad, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 16105 Manchester Rd, Ellisville, MO 63011 Phone: 636-391-3202 |